Leap Therapeutics Inc [NASDAQ: LPTX] price surged by 10.06 percent to reach at $0.03.
A sum of 23774393 shares traded at recent session while its average daily volume was at 1.40M shares. Leap Therapeutics Inc shares reached a high of $0.3794 and dropped to a low of $0.2517 until finishing in the latest session at $0.27.
The one-year LPTX stock forecast points to a potential upside of 95.09. The average equity rating for LPTX stock is currently 3.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Leap Therapeutics Inc [LPTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LPTX shares is $5.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LPTX stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for Leap Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 29, 2025. The new note on the price target was released on January 29, 2025, representing the official price target for Leap Therapeutics Inc stock. Previously, the target price had yet another raise to $8, while Rodman & Renshaw analysts kept a Buy rating on LPTX stock.
The Price to Book ratio for the last quarter was 1.94, with the Price to Cash per share for the same quarter was set at 0.44.
LPTX Stock Performance Analysis:
Leap Therapeutics Inc [LPTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.05. With this latest performance, LPTX shares dropped by -21.38% in over the last four-week period, additionally sinking by -47.22% over the last 6 months – not to mention a drop of -90.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LPTX stock in for the last two-week period is set at 39.18, with the RSI for the last a single of trading hit 0.0483, and the three-weeks RSI is set at 0.0406 for Leap Therapeutics Inc [LPTX]. The present Moving Average for the last 50 days of trading for this stock 0.3370, while it was recorded at 0.2972 for the last single week of trading, and 1.1990 for the last 200 days.
Leap Therapeutics Inc (LPTX) Capital Structure & Debt Analysis
According to recent financial data for Leap Therapeutics Inc. ( LPTX), the Return on Equity (ROE) stands at -183.72%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -129.47%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Leap Therapeutics Inc’s Return on Invested Capital (ROIC) is -1148.94%, showcasing its effectiveness in deploying capital for earnings.
Leap Therapeutics Inc (LPTX) Efficiency & Liquidity Metrics
Based on Leap Therapeutics Inc’s (LPTX) latest financial statements, the Debt-to-Equity Ratio is 0.05%, indicating its reliance on debt financing relative to shareholder equity.
Leap Therapeutics Inc (LPTX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Leap Therapeutics Inc. (LPTX) effectively leverages its workforce, generating an average of -$1263269.23 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.34% and a Quick Ratio of 1.34%, indicating strong ability to cover short-term liabilities.
LPTX Stock EPS
With the latest financial reports released by the company, Leap Therapeutics Inc posted -0.44/share EPS, while the average EPS was predicted by analysts to be reported at -0.47/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.03. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LPTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Leap Therapeutics Inc go to 32.77%.
Leap Therapeutics Inc [LPTX] Institutonal Ownership Details
There are presently around $31.08%, or 37.09%% of LPTX stock, in the hands of institutional investors. The top three institutional holders of LPTX stocks are: BALYASNY ASSET MANAGEMENT L.P. with ownership of 3.1 million shares, which is approximately 7.9238%. SAMSARA BIOCAPITAL, LLC, holding 2.44 million shares of the stock with an approximate value of $$4.79 million in LPTX stocks shares; and SAMSARA BIOCAPITAL, LLC, currently with $$2.55 million in LPTX stock with ownership which is approximately 3.3229%.
